These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25218571)

  • 1. Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia.
    Guo J; Cahill MR; McKenna SL; O'Driscoll CM
    Biotechnol Adv; 2014 Dec; 32(8):1396-409. PubMed ID: 25218571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-based nanoparticles in the systemic delivery of siRNA.
    Lin Q; Chen J; Zhang Z; Zheng G
    Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating multidrug resistance gene in leukaemia cells by short interfering RNA.
    Lim MN; Lau NS; Chang KM; Leong CF; Zakaria Z
    Singapore Med J; 2007 Oct; 48(10):932-8. PubMed ID: 17909680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics.
    Martirosyan A; Olesen MJ; Howard KA
    Adv Genet; 2014; 88():325-52. PubMed ID: 25409611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia.
    Guo J; Luan X; Cong Z; Sun Y; Wang L; McKenna SL; Cahill MR; O'Driscoll CM
    J Control Release; 2018 Sep; 286():154-166. PubMed ID: 30016734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
    Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
    Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical characterization techniques for lipid based delivery systems for siRNA.
    Kapoor M; Burgess DJ; Patil SD
    Int J Pharm; 2012 May; 427(1):35-57. PubMed ID: 21979250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.
    Zhao J; Feng SS
    Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?
    Guo J; Bourre L; Soden DM; O'Sullivan GC; O'Driscoll C
    Biotechnol Adv; 2011; 29(4):402-17. PubMed ID: 21435387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Powering up the molecular therapy of RNA interference by novel nanoparticles.
    Liao W; Li W; Zhang T; Kirberger M; Liu J; Wang P; Chen W; Wang Y
    Biomater Sci; 2016 Jun; 4(7):1051-61. PubMed ID: 27221980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of nanocarriers for the delivery of small interfering RNA.
    Kesharwani P; Gajbhiye V; Jain NK
    Biomaterials; 2012 Oct; 33(29):7138-50. PubMed ID: 22796160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes.
    Choi KM; Jang M; Kim JH; Ahn HJ
    Biomaterials; 2014 Aug; 35(25):7121-32. PubMed ID: 24854094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SiRNA delivery: challenges and role of carrier systems.
    Shegokar R; Al Shaal L; Mishra PR
    Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
    Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
    Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
    Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.